Our Journey

2022

June

OriCell Therapeutics reported Phase 1 study data of Ori-CAR017 in oral presentation at ASCO annual meeting 2022


May

OriCell Therapeutics's CAR-T clinical data accepted for presentation at 2022 European Hematology Association 2022 Congress

OriCell selected in Shanghai Professional, Refined, Specialized, Novel Businesses List


April

OriCell CAR-T Product Ori-CAR-017 Clinical Data Abstract Selected for Oral Presentation at ASCO 2022


March

OriCell announced the appointment of Dr. Weidong Cui as Chief Technology Officer

2021

November and October

OriCell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for poster presentation at the 2021 CSCO Annual Meeting


September 25

OriCell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for an oral presentation at the 2021 CSCO Annual Meeting


September

OriCell Therapeutics was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality


August

OriCell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality


June 7

The first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO


June 2

OriCell Therapeutics appointed Emily Tan, a senior expert in the field of strategy and clinical operations, as the company's executive vice president and COO


May

OriCell Medical Technology Co., Ltd. officially changed its name to "OriCell Therapeutics (Shanghai) Co., Ltd."

2020

December

OriCell Medical received the A round of financing of 202.138 million, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Osen Assets

OriCell Medical established the Shanghai Academician (Expert) Workstation


November

OriCell Medical established the Pudong New Area Enterprise Postdoctoral Research Workstation Substation


October

OriCell Medical won the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition


June

OriCell Medical was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

OriCell Medical reached a global development agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD


2019

December

OriCell Medical received the pre-A round of exclusive funding from Qiming Venture Partners


November

OriCell Medical became a co-construction unit of Shanghai Cell Therapy Clinical Transformation Engineering Technology Center

OriCell Medical became one of the funded key technology start-up enterprises in Pudong New Area


April

OriCell Medical was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

2018

November

OriCell Medical was recognized as a High- and New-Technology Enterprise

OriCell Medical received funding from the 2018 Pudong New Area Science and Technology Development Fund

The Secretary-General of the Nobel Prize Committee visited OriCell Medical


October

OriCell Medical attended the 2018 Chinese Conference on Translational Medicine and presented its independent R&D results in multiple fields


June

OriCell Medical's research results for CAR-T in liver cancer were published in the authoritative journal Protein & Cell


May

OriCell Medical signed a strategic cooperation agreement with an emerging enterprise in the domestic CAR-T industry, Beijing Yimiaoshenzhou Medical Technology Co., Ltd.


March

The Ministry of Science and Technology approved OriCell Medical as the principal institution to continue and complete the research project of the 973 Program titled "Research on New Intervention Strategies for Ankylosing Spondylitis"

2017

July

OriCell Medical in collaboration with Zhongshan Hospital carried out a series of clinical trials of the cell therapy technologies (among which CAR-T was the most notable) at the Zhongshan-OriCell Therapy Center, which was jointly constructed by the two units


May

Shanghai Changzheng Hospital and OriCell Medical joined hands again and established the "Changzheng - OriCell Clinical Research Center" at Shanghai Changzheng Hospital

2016

May

OriCell Medical established the CAR-T technology platform with high memory and high vitality


February

OriCell Medical expanded its R&D team

2015

February

OriCell Medical was founded by OriCell Group; the co-founder Dr. He Xiaowen served as the chief scientist

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015

2022

2021

2020

2019

2018

2017

2016

2015

2022

June

OriCell Therapeutics reported Phase 1 study data of Ori-CAR017 in oral presentation at ASCO annual meeting 2022


May

OriCell Therapeutics's CAR-T clinical data accepted for presentation at 2022 European Hematology Association 2022 Congress

OriCell selected in Shanghai Professional, Refined, Specialized, Novel Businesses List


April

OriCell CAR-T Product Ori-CAR-017 Clinical Data Abstract Selected for Oral Presentation at ASCO 2022


March

OriCell announced the appointment of Dr. Weidong Cui as Chief Technology Officer

2021

November and October

OriCell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for poster presentation at the 2021 CSCO Annual Meeting


September 25

OriCell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for an oral presentation at the 2021 CSCO Annual Meeting


September

OriCell Therapeutics was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality


August

OriCell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality


June 7

The first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO


June 2

OriCell Therapeutics appointed Emily Tan, a senior expert in the field of strategy and clinical operations, as the company's executive vice president and COO


May

OriCell Medical Technology Co., Ltd. officially changed its name to "OriCell Therapeutics (Shanghai) Co., Ltd."

2020

December

OriCell Medical received the A round of financing of 202.138 million, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Osen Assets

OriCell Medical established the Shanghai Academician (Expert) Workstation


November

OriCell Medical established the Pudong New Area Enterprise Postdoctoral Research Workstation Substation


October

OriCell Medical won the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition


June

OriCell Medical was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

OriCell Medical reached a global development agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD


2019

December

OriCell Medical received the pre-A round of exclusive funding from Qiming Venture Partners


November

OriCell Medical became a co-construction unit of Shanghai Cell Therapy Clinical Transformation Engineering Technology Center

OriCell Medical became one of the funded key technology start-up enterprises in Pudong New Area


April

OriCell Medical was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

2018

November

OriCell Medical was recognized as a High- and New-Technology Enterprise

OriCell Medical received funding from the 2018 Pudong New Area Science and Technology Development Fund

The Secretary-General of the Nobel Prize Committee visited OriCell Medical


October

OriCell Medical attended the 2018 Chinese Conference on Translational Medicine and presented its independent R&D results in multiple fields


June

OriCell Medical's research results for CAR-T in liver cancer were published in the authoritative journal Protein & Cell


May

OriCell Medical signed a strategic cooperation agreement with an emerging enterprise in the domestic CAR-T industry, Beijing Yimiaoshenzhou Medical Technology Co., Ltd.


March

The Ministry of Science and Technology approved OriCell Medical as the principal institution to continue and complete the research project of the 973 Program titled "Research on New Intervention Strategies for Ankylosing Spondylitis"

2017

July

OriCell Medical in collaboration with Zhongshan Hospital carried out a series of clinical trials of the cell therapy technologies (among which CAR-T was the most notable) at the Zhongshan-OriCell Therapy Center, which was jointly constructed by the two units


May

Shanghai Changzheng Hospital and OriCell Medical joined hands again and established the "Changzheng - OriCell Clinical Research Center" at Shanghai Changzheng Hospital

2016

May

OriCell Medical established the CAR-T technology platform with high memory and high vitality


February

OriCell Medical expanded its R&D team

2015

February

OriCell Medical was founded by OriCell Group; the co-founder Dr. He Xiaowen served as the chief scientist

18-month plan and important milestones

Subtitle: Make every step with resolution and move ahead persistently to achieve more

  • IND applications for several core products;

  • Carry out exploratory clinical studies to prove the safety and clinical validity of newly developed products.

3-5-year plan and important milestones

Advance with the original aspiration and never swerve in faith

2024/2025

Initial public offering

2025/2026

First tumor cell therapy product launch